Related references
Note: Only part of the references are listed.Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study
Takashi Wada et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2021)
Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial
Niels H. Brandt-Jacobsen et al.
DIABETES & METABOLISM (2021)
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2021)
Eplerenone Attenuates Fibrosis in the Contralateral Kidney of UUO Rats by Preventing Macrophage-to-Myofibroblast Transition
Yunzhao Xiong et al.
FRONTIERS IN PHARMACOLOGY (2021)
Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
George Bakris et al.
HYPERTENSION (2021)
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
Peter Kolkhof et al.
AMERICAN JOURNAL OF NEPHROLOGY (2021)
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
Frederic Jaisser et al.
FRONTIERS IN PHARMACOLOGY (2021)
From Proteinuria to Fibrosis: An Update on Pathophysiology and Treatment Options
Sonia Sharma et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2021)
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2021)
New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure
Irene Capelli et al.
JOURNAL OF NEPHROLOGY (2020)
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
A. J. Scheen
DIABETES & METABOLISM (2020)
Estimating lifetime benefits of comprehensive disease -modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
Muthiah Vaduganathan et al.
LANCET (2020)
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease BLOCK-CKD Trial
George Bakris et al.
HYPERTENSION (2020)
Podocytopathies
Jeffrey B. Kopp et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
The hemodynamic and metabolic effects of spironolactone treatment in acute kidney injury assessed by hyperpolarized MRI
Jakob Lykke Lindhardt et al.
NMR IN BIOMEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial
Hitoshi Minakuchi et al.
SCIENTIFIC REPORTS (2020)
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
Edmund Y. M. Chung et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)
Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat
Catherine J. Leader et al.
PHYSIOLOGICAL REPORTS (2020)
Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation
Jonatan Barrera-Chimal et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes
Dan Dong et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2019)
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Jonatan Barrera-Chimal et al.
KIDNEY INTERNATIONAL (2019)
Emerging therapeutic strategies for transplantation-induced acute kidney injury: protecting the organelles and the vascular bed
Nicolas Melis et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
Sadayoshi Ito et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice
Abdus Sattar Bhuiyan et al.
HYPERTENSION RESEARCH (2019)
Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats
Lei Li et al.
HYPERTENSION RESEARCH (2019)
Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials
Maria-Eleni Alexandrou et al.
JOURNAL OF HYPERTENSION (2019)
Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients
Line A. Mortensen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Spironolactone reduces oxidative stress in living donor kidney transplantation: a randomized controlled trial
Luis Eduardo Morales-Buenrostro et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
Marianne Lachaux et al.
DIABETES OBESITY & METABOLISM (2018)
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Merlin C. Thomas et al.
DIABETOLOGIA (2018)
Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity
Jana Grune et al.
HYPERTENSION (2018)
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Hans-Joachim Anders et al.
NATURE REVIEWS NEPHROLOGY (2018)
Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
Krister Bamberg et al.
PLOS ONE (2018)
The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial)
Line Aas Mortensen et al.
BMC NEPHROLOGY (2018)
EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial
Sophie Girerd et al.
TRIALS (2018)
Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease
Chen-Ta Yang et al.
JOURNAL OF CLINICAL MEDICINE (2018)
The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale
Alhasan Mujtaba et al.
CARDIOLOGY AND THERAPY (2018)
Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis
Byung Chul Yu et al.
KIDNEY RESEARCH AND CLINICAL PRACTICE (2018)
Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy
James Voelker et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease Role of Oxidative Stress
Lionel Lattenist et al.
HYPERTENSION (2017)
Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1
Jonatan Barrera-Chimal et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy
Clarice K. Fujihara et al.
SCIENTIFIC REPORTS (2017)
Chronic kidney disease
Paola Romagnani et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy
Mara Medeiros et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis
Davor Vukadinovic et al.
AMERICAN HEART JOURNAL (2017)
The Effect of Spironolactone on Acute Kidney Injury After Cardiac Surgery: A Randomized, Placebo-Controlled Trial
Ruben Barba-Navarro et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia
Jonatan Barrera-Chimal et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration
Cristian A. Amador et al.
KIDNEY INTERNATIONAL (2016)
Nephron Protection in Diabetic Kidney Disease
Hans-Joachim Anders et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
Gemma Currie et al.
BMC NEPHROLOGY (2016)
CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats
Kiyoshi Arai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Volker Vallon
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease
Thamarasee M. Jeewandara et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2015)
Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis
Jing Hou et al.
CLINICAL THERAPEUTICS (2015)
Nonsteroidal antagonists of the mineralocorticoid receptor
Peter Kolkhof et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2015)
Mild ischemic Injury Leads to Long-Term Alterations in the Kidney: Amelioration by Spironolactone Administration
Jonatan Barrera-Chimal et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2015)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628
Frank Y. Ma et al.
PLOS ONE (2015)
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Peter Kolkhof et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease
Louis L. Huang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Local Mineralocorticoid Receptor Activation and the Role of Rac1 in Obesity-Related Diabetic Kidney Disease
Shigetaka Yoshida et al.
NEPHRON EXPERIMENTAL NEPHROLOGY (2014)
Aldosterone antagonists for preventing the progression of chronic kidney disease
Davide Bolignano et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Mineralocorticoid Receptor Blockade Reduced Oxidative Stress in Renal Transplant Recipients: A Double-Blind, Randomized Pilot Study
Marcos Ojeda-Cervantes et al.
AMERICAN JOURNAL OF NEPHROLOGY (2013)
Aldosterone mediates glomerular inflammation in experimental mesangial proliferative glomerulonephritis
Danping Qin et al.
JOURNAL OF NEPHROLOGY (2013)
Eplerenone-Mediated Aldosterone Blockade Prevents Renal Fibrosis by Reducing Renal Inflammation, Interstitial Cell Proliferation and Oxidative Stress
Hui Chen et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2013)
Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury
Jonatan Barrera-Chimal et al.
KIDNEY INTERNATIONAL (2013)
The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity
Finn Thomsen Nielsen et al.
BMC NEPHROLOGY (2013)
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery
Mias Pretorius et al.
CRITICAL CARE MEDICINE (2012)
Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury
H. Tokuyama et al.
INTERNATIONAL JOURNAL OF OBESITY (2012)
Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat
Bruno S. Pessoa et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2012)
Mineralocorticoid Receptor Antagonism and Aldosterone Synthesis Inhibition Do Not Improve Glomerulosclerosis and Renal Interstitial Fibrosis in a Model of Chronic Kidney Allograft Injury
Tobias Lahmer et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Glomerular hyperfiltration: definitions, mechanisms and clinical implications
Imed Helal et al.
NATURE REVIEWS NEPHROLOGY (2012)
Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease
Michael Lian et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Recovery from ischemic acute kidney injury by spironolactone administration
Katy Sanchez-Pozos et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Antihypertensive and Cardiorenal Protective Effects of SM-368229, a Novel Mineralocorticoid Receptor Antagonist, in Aldosterone/Salt-Treated Rats
Tetsuro Nariai et al.
PHARMACOLOGY (2012)
Four danger response programs determine glomerular and tubulointerstitial kidney pathology Clotting, inflammation, epithelial and mesenchymal healing
Hans-Joachim Anders
ORGANOGENESIS (2012)
Chapter 1: Definition and classification of CKD
Kidney International Supplements (2012)
Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production
Jiro Toyonaga et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats
Femke Waanders et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Generation and evolution of atubular glomeruli in the progression of renal disorders
Robert L. Chevalier et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats
Finn Thomsen Nielsen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor - Role of oxidative stress
Miki Nagase et al.
HYPERTENSION (2007)
Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone
Juan M. Mejia-Vilet et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity
Jazmin Perez-Rojas et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats
Jun Yuan et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2007)
Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus
Christine Guo et al.
ENDOCRINOLOGY (2006)
Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats
K. H. Han et al.
KIDNEY INTERNATIONAL (2006)
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker
Miki Nagase et al.
HYPERTENSION (2006)
Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats
Sang-Youb Han et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well
Mustafa Gullulu et al.
RENAL FAILURE (2006)
Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity
JM Pérez-Rojas et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)
Regression of existing glomerulosclerosis by inhibition of aldosterone
JC Aldigier et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study
S Bianchi et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats
G Fujisawa et al.
KIDNEY INTERNATIONAL (2004)
Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-thy-1 irreversible nephritis
M Asai et al.
HYPERTENSION RESEARCH (2004)
Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model
XY Zhou et al.
AMERICAN JOURNAL OF NEPHROLOGY (2004)
Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction
H Trachtman et al.
JOURNAL OF UROLOGY (2004)
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats
ER Blasi et al.
KIDNEY INTERNATIONAL (2003)
Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity
I Feria et al.
KIDNEY INTERNATIONAL (2003)
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
NJ Brown et al.
KIDNEY INTERNATIONAL (2000)
Share Paper
